Christopher James Sampson : Citation Profile

Office of Health Economics

3

H index

0

i10 index

13

Citations

RESEARCH PRODUCTION:

8

Articles

11

Papers

RESEARCH ACTIVITY:

   11 years (2013 - 2024). See details.
   Cites by year: 1
   Journals where Christopher James Sampson has often published
   Relations with other researchers
   Recent citing documents: 2.    Total self citations: 1 (7.14 %)

EXPERT IN:

   Health
   Publicly Provided Goods
   Welfare Economics

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/psa1048
   Updated: 2026-01-10    RAS profile: 2025-04-24    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Towse, Adrian (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Christopher James Sampson.

Is cited by:

Dubois, Pierre (1)

Sculpher, Mark (1)

Lorgelly, Paula (1)

Shah, Koonal (1)

Magnac, Thierry (1)

Cites to:

Devlin, Nancy (4)

Brazier, John (4)

Brouwer, Werner (3)

Frew, Emma (3)

Tsuchiya, Aki (2)

Parkin, David (2)

Niessen, Louis (2)

Zamora Talaya, Bernarda (1)

Banerjee, Anindya (1)

Attema, Arthur (1)

Roberts, Jennifer (1)

Main data

Where Christopher James Sampson has published?

Journals with more than one article published# docs
PharmacoEconomics - Open2

Working Papers Series with more than one paper published# docs
Contract Research / Office of Health Economics4
MPRA Paper / University Library of Munich, Germany3
Briefing / Office of Health Economics2
Grant-Funded Research / Office of Health Economics2

Recent works citing Christopher James Sampson (2025 and 2024)

YearTitle of citing document
2024Optimal intertemporal curative drug expenses: The case of hepatitis C in France. (2024). Magnac, Thierry ; Dubois, Pierre. In: Journal of Health Economics. RePEc:eee:jhecon:v:94:y:2024:i:c:s0167629624000067.

Full description at Econpapers || Download paper

2024‘Managing values’ in health economics modelling: Philosophical and practical considerations. (2024). Winsberg, Eric B ; Harvard, Stephanie. In: Social Science & Medicine. RePEc:eee:socmed:v:358:y:2024:i:c:s027795362400710x.

Full description at Econpapers || Download paper

Works by Christopher James Sampson:

YearTitleTypeCited
2024Marginal cost per QALY estimates: What are they good for? In: Health Policy.
[Full Text][Citation analysis]		article0
2019How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefing.
[Citation analysis]		paper3
2021How is Quality of Life Measured for Health Technology Assessments? In: Briefing.
[Full Text][Citation analysis]		paper0
2018Barriers to Uptake of Minimal Access Surgery in the United Kingdom In: Contract Research.
[Full Text][Citation analysis]		paper0
2018The Impact of New Medicines in the NHS: 70 Years of Innovation In: Contract Research.
[Full Text][Citation analysis]		paper0
2023The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe In: Contract Research.
[Full Text][Citation analysis]		paper0
2024A Framework for Value-aligned Pricing of Combination Therapies In: Contract Research.
[Full Text][Citation analysis]		paper0
2018R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Grant-Funded Research.
[Full Text][Citation analysis]		paper1
2020Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation? In: Grant-Funded Research.
[Full Text][Citation analysis]		paper0
2013Cost implications of treatment non-completion in a forensic personality disorder service In: MPRA Paper.
[Full Text][Citation analysis]		paper0
2013Happy and healthy: a joint model of health and life satisfaction In: MPRA Paper.
[Full Text][Citation analysis]		paper0
2013The relationship between individual risk and cost-effectiveness in screening interventions In: MPRA Paper.
[Full Text][Citation analysis]		paper0
2021Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al. In: Medical Decision Making.
[Full Text][Citation analysis]		article1
2022Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]		article0
2013Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776 In: The European Journal of Health Economics.
[Full Text][Citation analysis]		article0
2019Transparency in Decision Modelling: What, Why, Who and How? In: PharmacoEconomics.
[Full Text][Citation analysis]		article4
2017Model Registration: A Call to Action In: PharmacoEconomics - Open.
[Full Text][Citation analysis]		article4
2022NICE and the EQ-5D-5L: Ten Years Trouble In: PharmacoEconomics - Open.
[Full Text][Citation analysis]		article0
2024Is anchoring at ‘dead’ a theoretical requirement for health state valuation? In: Health Economics.
[Full Text][Citation analysis]		article0

CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated December, 22 2025. Contact: CitEc Team